RxDoctor Payments Data

Roman Galysh, MD

Gastroenterology · Rome, GANPI 1235348004

Payments from drug & device makers

$1,370in general payments, 2019–2025

Across 88 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$349
  • AbbVie$313
  • Takeda Pharmaceuticals U.S.A., Inc.$161
  • Fujifilm Healthcare Americas Corporation$142
  • Boston Scientific$128
  • Intercept Pharmaceuticals, Inc.$71
  • plus $207 from 10 others

What the payments were for

  • Consulting fees$161%
  • Food & beverage$1,20088%
  • Education$131%
  • Other$14210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,370 in reported general payments places this provider in the 25th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$141,148
Medicare patients
652
Services billed
1,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab12$81,410
LinzessLinaclotide55$51,137
XifaxanRifaximin15$50,776
CreonLipase/Protease/Amylase25$31,678
MovantikNaloxegol Oxalate19$10,852
Colestipol Hcl63$8,234
Mesalamine16$6,589
Dexlansoprazole DrDexlansoprazole16$5,131
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl281$4,411
Lubiprostone31$4,376
Alosetron Hcl12$3,317
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl185$2,931
Ursodiol30$2,663
Pantoprazole Sodium206$2,337
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C15$2,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$313$82,81580 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$349$52,87530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →